INT3040

From wiki-pain
Revision as of 06:52, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.24
First Reported 1977
Last Reported 2010
Negated 4
Speculated 5
Reported most in Body
Documents 81
Total Number 91
Disease Relevance 53.61
Pain Relevance 12.62

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endoplasmic reticulum (MIA3)
Anatomy Link Frequency
plasma 22
blood 10
cleavage 2
erythrocytes 1
endocrine cell 1
MIA3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Somatostatin 35 100.00 Very High Very High Very High
Dynorphin 12 99.92 Very High Very High Very High
Chronic pancreatitis 43 99.86 Very High Very High Very High
tolerance 50 99.44 Very High Very High Very High
Sumatriptan 12 99.18 Very High Very High Very High
Bile 3 99.04 Very High Very High Very High
qutenza 7 98.96 Very High Very High Very High
Migraine 12 98.84 Very High Very High Very High
Angina 18 98.46 Very High Very High Very High
diabetic neuropathy 138 97.28 Very High Very High Very High
Disease Link Frequency Relevance Heat
Pancreatic Cancer 18 99.98 Very High Very High Very High
Pancreatitis 58 99.86 Very High Very High Very High
Generalized Anxiety Disorder 29 99.80 Very High Very High Very High
Increased Venous Pressure Under Development 8 99.74 Very High Very High Very High
Diabetes Mellitus 1471 99.50 Very High Very High Very High
Metabolic Disorder 2 99.24 Very High Very High Very High
Atherosclerosis 240 99.20 Very High Very High Very High
Hypoglycemia 212 99.20 Very High Very High Very High
Myocardial Infarction 6 99.10 Very High Very High Very High
Diabetes Mellitus-type I 56 99.02 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The plasma levels of insulin and C-peptide increased from 90 to 165 min after glucose loading but there were no significant difference between the results obtained without and with capsaicin administration.
Gene_expression (levels) of C-peptide in plasma associated with qutenza
1) Confidence 0.24 Published 2006 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16612838 Disease Relevance 0 Pain Relevance 0.56
In lean subjects epinephrine produced significant increases in plasma glucose levels, but no appreciable changes in plasma insulin, C-peptide, or glucagon.
Neg (no) Gene_expression (produced) of C-peptide in plasma
2) Confidence 0.23 Published 1988 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 2969000 Disease Relevance 0.61 Pain Relevance 0.12
In the same subjects, beta-endorphin produced elevations of plasma glucose, insulin, C-peptide, and glucagon.
Gene_expression (produced) of C-peptide in plasma
3) Confidence 0.23 Published 1988 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 2969000 Disease Relevance 0.26 Pain Relevance 0
In the case of type 1 diabetes, available data suggest that C-peptide deficiency is an important
Gene_expression (deficiency) of C-peptide associated with diabetes mellitus
4) Confidence 0.16 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 1.72 Pain Relevance 0.09
type 2 diabetes often become insulin and C-peptide deficient, and at this stage
Gene_expression (deficient) of C-peptide associated with diabetes mellitus
5) Confidence 0.16 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 1.71 Pain Relevance 0.07
significant physiological effects of C-peptide has been presented during the
Gene_expression (effects) of C-peptide
6) Confidence 0.16 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 1.08 Pain Relevance 0.05
It shows that C-peptide, in contrast to previous belief,
Gene_expression (shows) of C-peptide
7) Confidence 0.16 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 0.99 Pain Relevance 0.05
The infusion of synthetic human beta-endorphin (4.5 ng/kg/min) produced the following: (1) in normal-weight subjects, no significant change of plasma glucose and pancreatic hormones (insulin, C-peptide, and glucagon), a significant plasma free fatty acids (FFA) increase, and a suppression of glycerol plasma levels; (2) in obese subjects, significant increases of glucose, insulin, C-peptide, and glucagon, a progressive decline of circulating FFA, and no change in glycerol plasma levels.
Neg (no) Gene_expression (produced) of C-peptide in plasma associated with obesity
8) Confidence 0.15 Published 1992 Journal Metab. Clin. Exp. Section Abstract Doc Link 1736041 Disease Relevance 0.34 Pain Relevance 0.10
replacement dose to patients lacking endogenous C-peptide results in
Neg (lacking) Gene_expression (results) of C-peptide
9) Confidence 0.14 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 0.40 Pain Relevance 0.03
significant improvement in SCV for the patients receiving C-peptide, amounting to
Gene_expression (receiving) of C-peptide
10) Confidence 0.14 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 0.34 Pain Relevance 0.04
revealed that among patients receiving C-peptide, 39% demonstrated an improvement in
Gene_expression (receiving) of C-peptide
11) Confidence 0.14 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 0.06 Pain Relevance 0
The available clinical results indicate beneficial effects of C-peptide on both peripheral and autonomic nerve
Gene_expression (effects) of C-peptide in nerve
12) Confidence 0.14 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 0.61 Pain Relevance 0
Thus, it has been demonstrated that exogenous administration of C-peptide in
Gene_expression (administration) of C-peptide
13) Confidence 0.14 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 0.46 Pain Relevance 0.04
reference value 24%) and during the C-peptide infusion which restored plasma concentrations
Gene_expression (infusion) of C-peptide in plasma
14) Confidence 0.14 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 0.40 Pain Relevance 0
scores following C-peptide.
Gene_expression (following) of C-peptide
15) Confidence 0.14 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 0.32 Pain Relevance 0
diabetes duration of 10 years) where 3 months of C-peptide replacement resulted in 2.7 m/s improvement in
Gene_expression (replacement) of C-peptide associated with diabetes mellitus
16) Confidence 0.14 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 0.78 Pain Relevance 0.03
peripheral nerve dysfunction following C-peptide administration in patients with type 1
Gene_expression (administration) of C-peptide in peripheral nerve
17) Confidence 0.14 Published 2008 Journal Experimental Diabetes Research Section Body Doc Link PMC2266809 Disease Relevance 0.36 Pain Relevance 0
Sumatriptan significantly decreased the mean plasma levels of somatostatin, glucagon, pancreatic polypeptide, insulin and C-peptide (P < 0.001) and also significantly decreased mean and peak plasma levels of insulin after an oral glucose challenge (P < 0.02 and P = 0.04, respectively) without affecting glucose homeostasis.
Gene_expression (levels) of C-peptide in plasma associated with sumatriptan and somatostatin
18) Confidence 0.14 Published 1998 Journal Am. J. Physiol. Section Abstract Doc Link 9486164 Disease Relevance 0.09 Pain Relevance 0.68
To elucidate the influence of 5-hydroxytryptamine-1 receptor activation by sumatriptan on endocrine pancreatic function and blood glucose homeostasis, we determined plasma levels of somatostatin, glucagon, pancreatic polypeptide, insulin, and C-peptide before and after subcutaneous administration of sumatriptan (6 mg) in seven healthy volunteers, and we measured blood glucose and insulin plasma levels during an oral glucose tolerance test after placebo and after subcutaneous administration of sumatriptan (6 mg) in seven healthy volunteers.
Spec (determined) Gene_expression (levels) of C-peptide in blood associated with sumatriptan, tolerance, somatostatin and impaired glucose tolerance
19) Confidence 0.12 Published 1998 Journal Am. J. Physiol. Section Abstract Doc Link 9486164 Disease Relevance 0.09 Pain Relevance 0.71
[Trypsin and C-peptide concentration in the blood serum of patients with chronic pancreatitis].
Gene_expression (concentration) of C-peptide in blood associated with chronic pancreatitis
20) Confidence 0.10 Published 1989 Journal Vrach Delo Section Title Doc Link 2800495 Disease Relevance 0.29 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox